Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.55 |
| ▸ | NEK2 | P51955 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5258578 | 0.98 | CRBN (0.53) | CRBNNEK2DDB1TSHRNPSR1 | |
| SCHEMBL5393521 | 0.86 | CRBN (0.68) | CRBNNEK2DDB1TSHRNPSR1 | |
| SCHEMBL278097 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL23067561 | 0.85 | CRBN (0.66) | CRBNNEK2DDB1TSHRNPSR1 | |
| SCHEMBL278231 | 0.80 | CRBN (0.41) | CRBNDDB1TSHRNPSR1IDO1 | |
| SCHEMBL22018269 | 0.79 | CRBN (0.77) | CRBNNEK2 | |
| SCHEMBL3825820 | 0.78 | CRBN (0.40) | CRBNDDB1TSHRNPSR1 | |
| SCHEMBL3958832 | 0.78 | CRBN (0.40) | CRBNDDB1TSHRNPSR1 | |
| SCHEMBL9688503 | 0.77 | CRBN (0.38) | CRBNNEK2 | |
| SCHEMBL17077711 | 0.74 | CRBN (0.38) | CRBNDDB1TSHRNPSR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113135921-B | Dihydropyrimidine-spiro derivative and preparation method and application thereof | 山东大学 | 2022-06-17 | — | — | CN | claimed |
| EP-3122739-A1 | PYRIDYL PIPERIDINES | Merck Patent GmbH (DE) | 2017-02-01 | — | — | EP | claimed |
| WO-2015144290-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | WO | claimed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | claimed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| CN-110612294-B | Human cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023215802-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | disclosed |
| US-6693109-B2 | SUCH AS ETHYL(3-(4-(AMINOIMINOMETHYL)PHENYL)-1-OXA-2,8-DIAZA-SPIRO(4.5)DEC-2-EN-8 -YL)ACETATE | ELI LILLY AND COMPANY | 2004-02-17 | — | — | US | disclosed |
| US-20030171373-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2003-09-11 | — | — | US | disclosed |
| US-6528534-B2 | Useful as glycoprotein IIb/IIIa antagonists for prophylaxis thrombosis, therapy of atheroschlerosis, arterioschlerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2002-01-31 | — | — | US | disclosed |
| US-6291469-B1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | ELI LILLY AND COMPANY | 2001-09-18 | — | — | US | disclosed |
| EP-0854869-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011940-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | CRBN 1/4885NEK2 466/4885DDB1 143/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885NEK2 818/4885DDB1 706/4885 |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CRBN 179/4885NEK2 958/4885DDB1 987/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885NEK2 818/4885DDB1 706/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885NEK2 729/4885DDB1 576/4885 |
| US-20030171373-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | CRBN 3736/4885NEK2 1046/4885DDB1 2887/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885NEK2 818/4885DDB1 706/4885 |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | CRBN 3736/4885NEK2 1046/4885DDB1 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.